Agilent launches NovoStation to automate flow-cytometry sample preparation
Summary
Agilent launched the NovoStation Sample Preparation System on 1 October 2026, automating reagent cocktailing, staining, washing and other flow-cytometry sample-preparation steps and linking with compatible NovoCyte instruments.
The evidence
Agilent announced NovoStation on 1 October 2026 and maintains a current product page with a Request Quote workflow. The system sits in Agilent's Research Flow Cytometry portfolio and can run standalone or integrate with compatible NovoCyte flow cytometers. It automates reagent cocktailing, staining, washing, lysis, fixation and permeabilization, and supports 96-well workflows, barcoding, event logging, cooling and role-based permissions.
CFCM EXPLAINER — MOVING STANDARDISATION UPSTREAM
Manual cocktailing + staining + washing → NovoStation automated preparation → compatible NovoCyte acquisition → NovoExpress analysis.
Source/credit: CFCM schematic based on Agilent primary product information, checked 2 October 2026. Alt text: workflow showing automated sample preparation before flow-cytometry acquisition and analysis.
Agilent reports that internal validation reduced hands-on time by more than 90% while maintaining data quality comparable with manual preparation. Its examples include 7.9 versus 85.5 minutes of operator time for a 30-sample, 25-color immunophenotyping workflow and 6.8 versus 89.4 minutes for a kappa/lambda light-chain workflow.
Interpretation and limitations
The time-saving and comparability results are manufacturer-generated validation/application data, not independent multicentre clinical validation. The cited launch release and product page do not establish CE-IVD or FDA diagnostic authorization for NovoStation, so CFCM does not infer an IVD status. Automation may reduce operator-dependent variation, but local assay validation must still address specimen handling, reagent lots, staining performance, carryover, timing, wash efficiency and downstream acquisition/analysis.
What this means for laboratories
Sample preparation is a major source of pre-analytical variation in flow cytometry. NovoStation therefore matters as more than a labour-saving device: it is another move toward integrated sample-to-answer architecture. The key question for clinical-flow laboratories will be whether automated preparation produces reproducible staining and acceptable analytical performance across operators, days, lots, instruments and sites.
Source Date
October 1, 2026
Event date
October 1, 2026
Commercial Regulatory Status
Commercially offered via Agilent Request Quote in the Research Flow Cytometry portfolio. No CE-IVD or FDA diagnostic authorization identified in the cited primary sources.
Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.
Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.
Original CFCM conceptual illustration · No experimental cell data
A · Two measurement contexts
B · Compare marker representations
C · Candidate correspondence
D · Read the metric in context
Comparing phenotypes, not proving clinical interchangeability. A–C illustrate measurement contexts, shared marker representations and candidate correspondences. Shapes and coloured tiles are conceptual symbols, not cell-level observations, expression measurements or match probabilities. D places the abstract-reported median F1 of 0.81 on its 0–1 scale for cross-platform immune-cell identification between IMC and CyTOF. Results vary with search direction and reference phenotype. F1 is not the percentage of all cells correctly classified and does not establish prospective clinical diagnostic validation. Original artwork: CFCM, 2026; no third-party figure reproduced.